Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 2011

View Archived Issues

MEGF-0444A is safe as monotherapy or combined with bevacizumab/paclitaxel in solid tumors

Interim first-in-human data support immunological efficacy of EMD-640744 in advanced solid tumors

Takeda presents new agents for treatment of diabetes

Phase III data on lipegfilgrastim for reduction of neutropenia in breast cancer

Enrollment complete in phase II CRMD-001 trial in contrast-induced acute kidney injury

Rozrolimupab well tolerated and active in patients with primary immune thrombocytopenia

Phase I/II data on navitoclax in lymphoid malignancies updated

Veliparib/temozolomide combination is safe in metastatic unresectable CRC

Lithostathine-1-alpha as a new biomarker in rheumatoid arthritis

Novel photosensitizing agents prepared at Mallinckrodt

Merck & Co. claims new hydroxycarboxylic acid HCA2 receptor agonists

Novel acetyl-CoA carboxylase inhibitors prepared by Pfizer

Roche team synthesizes novel glycogen synthase activators

Synageva BioPharma and Trimeris enter into merger agreement

Arecor and GSK join forces to develop new vaccine formulations

Resverlogix to begin phase IIb ASSURE trial of RVX-208

Abstral launched in Canada for breakthrough cancer pain

Dosing begins in first-in-human trial of VIA-3196 for dyslipidemia

Pathfast cTnI-II (cardiac troponin I) diagnostic test cleared in U.S.

APR and Labtec regain rights to ondansetron oral dispersible film

Adaptimmune begins phase I/II trial of genetically modified T-cell therapies in metastatic melanoma

FDA clears Inform Dual ISH test to help identify candidates for breast cancer therapy Herceptin

FDA accepts for review Novartis' application to expand Menveo indication to infants and toddlers

Nulojix approved in U.S. for prevention of acute kidney transplant rejection in adults

Sprycel indication expanded in Japan to include first-line treatment of chronic myeloid leukemia

Depakene approved in Japan to suppress onset of migraine attacks

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...